Revvity Inc. $RVTY Shares Bought by Triodos Investment Management BV

Key Points

• Triodos Investment Management BV increased its stake in Revvity Inc. by 27.1% in Q2, owning 37,500 shares valued at approximately $3.6 million.
• Various institutional investors have modified their holdings, with T. Rowe Price and EdgePoint Investment Group notably increasing their stakes by 8.5% and 32.1% respectively.
• Revvity reported earnings per share of $1.18 for the last quarter, exceeding expectations, along with a 4.1% year-over-year revenue increase.

Triodos Investment Management BV grew its stake in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 27.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,500 shares of the company's stock after acquiring an additional 8,000 shares during the quarter. Triodos Investment Management BV's holdings in Revvity were worth $3,627,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. increased its stake in shares of Revvity by 8.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company's stock valued at $2,382,163,000 after acquiring an additional 1,754,403 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Revvity by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 14,382,849 shares of the company's stock valued at $1,521,705,000 after acquiring an additional 92,638 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Revvity by 25.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company's stock valued at $1,011,863,000 after acquiring an additional 1,932,314 shares during the last quarter. EdgePoint Investment Group Inc. increased its stake in shares of Revvity by 32.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 5,360,847 shares of the company's stock valued at $567,178,000 after acquiring an additional 1,302,616 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Revvity by 1.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,444,645 shares of the company's stock valued at $364,443,000 after acquiring an additional 62,307 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on RVTY. Weiss Ratings downgraded shares of Revvity from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday. Stifel Nicolaus dropped their target price on shares of Revvity from $120.00 to $110.00 and set a "hold" rating for the company in a research report on Tuesday, July 29th. Barclays cut their target price on shares of Revvity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Raymond James Financial restated an "outperform" rating and set a $115.00 target price (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Finally, Evercore ISI reduced their target price on shares of Revvity from $108.00 to $106.00 and set an "outperform" rating on the stock in a report on Tuesday. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $117.93.

Revvity Stock Down 0.1%

NYSE RVTY opened at $91.64 on Friday. The stock has a market cap of $10.64 billion, a PE ratio of 38.83, a P/E/G ratio of 3.06 and a beta of 0.98. Revvity Inc. has a fifty-two week low of $81.36 and a fifty-two week high of $129.50. The business has a 50 day moving average price of $88.08 and a two-hundred day moving average price of $93.06. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.04. The firm had revenue of $720.28 million during the quarter, compared to analysts' expectations of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.Revvity's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. As a group, sell-side analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity's dividend payout ratio is 11.86%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.